Tag

Cancer Treatment

21 genetic variants with this tag.

RSID	Gene	Description	Category
rs1113129	CYP2C8	Intronic tagging SNP for CYP2C8 haplotype C, a low-activity haplotype associa...	Pharmacogenomics	Cancer Treatment	Moderate
rs1051298	SLC19A1 SLC19A1 3'UTR variant (c.*746C>T)	3'UTR variant in the folate transporter gene affecting pemetrexed toxicity ri...	Methylation & Detox	Cancer Treatment	Moderate
rs116855232	NUDT15 Arg139Cys	Nucleotide diphosphatase that inactivates toxic thiopurine metabolites; reduc...	Pharmacogenomics	Cancer Treatment	Established
rs12721627	CYP3A4 *16	Missense variant reducing CYP3A4 enzyme activity by 50–74% depending on subst...	Pharmacogenomics	Cancer Treatment	Moderate
rs12721629	CYP3A4 *16B	Missense variant causing substrate-dependent reduced CYP3A4 activity, most pr...	Pharmacogenomics	Cancer Treatment	Moderate
rs1341162	CYP2C8	Intronic CYP2C8 haplotype-tagging variant linked to altered drug metabolism c...	Pharmacogenomics	Cancer Treatment	Moderate
rs1341164	CYP2C8	Intronic CYP2C8 variant tagging a haplotype associated with altered taxane dr...	Pharmacogenomics	Cancer Treatment	Emerging
rs4775936	CYP19A1 CYP19A1 Promoter Region Variant (Aro1)	Regulatory variant in the CYP19A1 aromatase gene that alters estrogen biosynt...	Reproductive Hormones	Cancer Treatment	Moderate
rs1934951	CYP2C8	Intronic CYP2C8 variant associated with paclitaxel-induced toxicity and bisph...	Pharmacogenomics	Cancer Treatment	Moderate
rs396991	FCGR3A V158F	Missense variant in Fc gamma receptor IIIa (CD16a) that determines NK cell Ig...	Innate Immunity & Infection Defense	Cancer Treatment	Strong
rs1934980	CYP2C8	Intronic CYP2C8 variant linked to altered enzyme expression and associated wi...	Pharmacogenomics	Cancer Treatment	Moderate
rs28399433	CYP2A6 *9 (TATA box)	Promoter variant that reduces CYP2A6 expression by ~50%, slowing nicotine met...	Pharmacogenomics	Cancer Treatment	Strong
rs28399444	CYP2A6 *7 (I471T)	CYP2A6*7 missense variant that nearly abolishes nicotine C-oxidase activity; ...	Pharmacogenomics	Cancer Treatment	Established
rs3788189	SLC19A1 SLC19A1 IVS2 variant	Intronic variant in the folate transporter gene associated with pemetrexed tr...	Methylation & Detox	Cancer Treatment	Emerging
rs3918290	DPYD *2A	Most critical pharmacogenomic variant causing complete loss of DPD enzyme fun...	Pharmacogenomics	Cancer Treatment	Established
rs4148323	UGT1A1 *6 Gly71Arg	Phase II glucuronidation enzyme that metabolizes bilirubin and many drugs inc...	Pharmacogenomics	Cancer Treatment	Established
rs55886062	DPYD *13	No-function DPYD star allele (I560S) causing severe DPD deficiency; one of fo...	Pharmacogenomics	Cancer Treatment	Established
rs56038477	DPYD HapB3 tag (c.1236G>A, E412E)	Synonymous exon-11 tag SNP for the DPYD HapB3 haplotype; benign on its own bu...	Pharmacogenomics	Cancer Treatment	Established
rs67376798	DPYD D949V	Decreased-function variant reducing DPD enzyme activity ~30%, requiring 50% f...	Pharmacogenomics	Cancer Treatment	Established
rs67784355	CYP3A4 *11 (Thr363Met)	Rare missense variant in CYP3A4 that reduces protein expression and enzymatic...	Pharmacogenomics	Cancer Treatment	Emerging
rs75017182	DPYD HapB3 (c.1129-5923C>G)	Deep intronic splice-site variant that is the functional driver of the DPYD H...	Pharmacogenomics	Cancer Treatment	Established